Loading...
•
Dec 31, 2021
Immunovant Q3 2022 Earnings Report
Reported financial results with cash of approximately $527.0 million.
Key Takeaways
Immunovant reported its financial results for the fiscal quarter ended December 31, 2021. The company ended the quarter with approximately $527.0 million in cash. Net loss was $41.4 million, or $0.36 per common share.
Ended the quarter with approximately $527.0 million in cash.
Research and development expenses were $29.8 million.
General and administrative expenses were $11.5 million.
Net loss was $41.4 million ($0.36 per common share).
Forward Guidance
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...